Sanofi Backs Novadiscovery In Silico Trial Platform
French Biotech Raises €2.5m
Executive Summary
Novadiscovery has received funding from Sanofi and will support the French major’s COVID-19 efforts with its virtual JINKO clinical trial platform.
You may also be interested in...
Why 2020 Saw The Steady Rise Of In Silico Trials
Disruptions to clinical research during the COVID-19 pandemic has kindled a new level interest in using computer simulations to predict clinical trial outcomes. Regulatory guidance on “good simulation practices” can move things up a notch in this emerging field.
Coronavirus Update: Sanofi And GSK’s Vaccine Suffers Setback
While the new mRNA-based vaccines grow closer to market, Sanofi and GSK's more established approach experiences a serious setback.US authorization in sight for Pfizer/BioNTech after positive advisory committee vote. Pfizer Seeks More Time For EUA Presentation In India.
Regular Acceptance Of Simulation Studies More Likely In 2020s
Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.